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ABSTRACT
Peritoneal dialysis (PD) has been used for nearly 30 years as an effective treatment for end-stage
renal disease. During this period, there was a lot of improvement in the delivery system but there
was not much change in the composition of the dialysis solutions. There was increasing evidence
showing that the conventional PD solutions were bioincompatible. They adversely affect the
peritoneal immune system and make patients more prone to peritonitis. In addition, chronic exposure
to such solutions may lead to continuous peritoneal damage. All these factors are harmful to the
peritoneal membrane and impair its function as a dialysis membrane. There are now more attention
being paid to look for an ideal biocompatible PD fluid. The potential areas for improvement are the
buffer and osmotic agent, the ionic composition of the fluids, additives to the fluids and gene
therapy.
Key words: Biocompatibility, Peritoneal dialysis (PD) fluids, Continuous ambulatory peritoneal dialysis (CAPD)
 !
 !"#$%&'()*+%,-./01234567PM !"#$%&'()*+,-.
 !"#$%&'()*+,-./0/+&1234!56&78#$%.9:;<=>-
 !"#$%&'()*+,-./0123456789:;<*=412>34?@A'(
 !"#$%&'()*+,-./0123456789:";<=!>?@AB89:
 !"#$%&'()*+,-.$/012!,3'456789:
R E V I E W
A T R I C L E
Correspondence: Dr. Laurence CHAN, Campus Box C281, University of Colorado Health Sciences Center, 4200 East Ninth Avenue,
Denver, Col 80262, USA. Fax: (303) 270 4852, E-mail: Larry.chan@uchsc.edu
Hong Kong Journal of Nephrology
1999;1(1):4-10.
Hong Kong Journal of Nephrology, October 1999
INTRODUCTION
Peritoneal dialysis (PD) has been used for nearly 30 years
as an effective treatment for chronic end-stage renal
disease. During this period, there was a lot of
improvement in the delivery systems, such as catheter,
connecting devices and automated delivery system. But
there was not much change in the composition of the PD
solutions.
PD in early 1900s was performed using intravenous
solutions that were available during that period. Such
solutions include 0.8% saline, 5% dextrose and Ringer's
lactate and they will cause complications like pulmonary
edema, electrolyte and acid-base disturbances. Then in
the next coming 20 to 30 years, there were studies
revealing that the composition of PD fluid must be similar
to that of interstitial fluid and the solutions should be
made hypertonic with respect to blood to provide
ultrafiltration. Glucose was chosen out of several osmotic
agents, as it was safe and effective. The composition of
the standard PD solution used today is not much different
from the PD solutions that were used in the 1940s and
1950s (1). The solutions have low pH (5.2-5.5), high
osmolality, excessive glucose concentration and contain
lactate as buffers (Table 1). Despite these developments,
these solutions are unphysiological and the key question
is whether repeated exposure to such solutions will lead
to a functional impairment of the different cells and
structure of the peritoneum. According to Holmes (2),
the biocompatibility of PD is its biological effect on the
normal functioning of tissues and peritoneal cells, in the
presence or absence of infection. Then there was another
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more general definition of biocompatibility which was
suggested by the "Consensus Conference on
Biocompatibility" (Konigswinter, Germany, March 25-
27, 1993). The definition was " the ability of a material,
device, or system to perform without a clinically
significant host response". The first report on
biocompatibility of PD fluid was published in 1981
describing an inhibition of phagocyte function following
in vitro exposure to dialysis fluids (3). Since then, there
were more and more articles published investigating the
effects of dialysis fluids on various biological systems,
especially the peritoneal host defense system and the
peritoneal membrane function. The purpose of this article
is to review the current literature dealing with different
aspects of dialysis fluid biocompatibility and the future
trend of PD solutions.
SHORT-COMING OF CURRENT
PD FLUIDS
Most of the current solutions are hyperosmolar with low
pH, using lactate as buffer and glucose as the osmotic
agent. Such solutions are un-physiological and they can
adversely affect the peritoneal immune system,
predisposing the patients to peritonitis. They also impair
the process of re-mesothelization subsequent to
peritonitis (4). In addition, chronic exposure to such un-
physiological solutions may lead to a continuous
peritoneal damaging process followed by healing. This
is evidenced by the fact that the dialysate effluent from
peritonitis-free continuous ambulatory peritoneal dialysis
(CAPD) patients contain several mediators of
inflammation, such as prostaglandin, cytokine and their
soluble receptors and granulocyte-inhibiting or
granulocyte-activating protein. Furthermore, there is an
increased level of hyaluronan in the drained effluent from
CAPD patients (5). This is an index of continuous process
of peritoneal damaging followed by healing. Lastly, the
peritoneal biopsy specimens from CAPD patients reveal
morphological changes, providing evidence of
continuous injury to the mesothelial cells during chronic
PD and its subsequent regeneration (6).
NEW STRATEGIES FOR PD FLUIDS
As the current PD solutions have their limitations and
are bioincompatible, researchers are trying to find
strategies to improve the current PD solutions. The ideal
PD fluids should fulfill the following aims:
1. Nutritional support;
2. Help the clinical management of cardiovascular risk;
3. Preserve the peritoneal membrane structure;
4. No inhibitory effect on the peritoneal immune system;
5. Provide adequacy of PD.
Strategies to improve dialysis fluids include
improvement in biocompatibility, pH control using
appropriate buffer, volume homeostasis with suitable
osmotic agents and maintenance of ionic composition.
Effect of Buffer and pH
It is well established from the in vitro studies that low
pH in combination with lactate significantly impairs
some important functions of peritoneal and peripheral
leukocytes. These functions include phagocytosis,
bactericidal activity, oxidative respiratory burst
metabolism and leukotriene synthesis (2,7). Such effects
may not be seen in vivo since the pH (initial pH 5.2-5.5)
is rapidly equilibrated within the first 20 to 30 minutes
and the lactate concentration drops with increasing dwell
time. Furthermore, there will be protective effect of the
protein-rich residual fluid volume (8).
de Fijter et al (9) demonstrated that the inhibitory effects
on phagocyte function by pH/lactate and high osmolality/
glucose persisted even after a 60-to-90-minute dwell
period in vivo, by which time the infused PD fluid should
be equilibrated. These observations suggest that the
inhibitory effect on phagocyte function do occur in vivo
and indicate that even short time exposure to PD fluid
may be sufficient to modulate cell function despite the
equilibration process.
There are two proposed mechanisms for lactate toxicity.
The first one involves the intracellular acidification by
lactate. Lactate and lactic acid are in an equilibrium
Table 1. Compostition of peritoneal dialysis solutions of different periods.
Ganter Wear, Sisk, Trinkle Odel, Ferris, Power Boen Present
1920s 1930s 1940s 1950s 1990s
Na mmol/L 136 130 151 135 132-134
K mmol/L 0 4 3 0 0-2
Cl mmol/L 136 110 145 107.5 95-106
Ca mmol/L 0 2 1 1.5 1.25-1.75
Glucose g/dL  0 0 1.5 2.0 or higher 1.5-4.25
Acet/lact mmol/L 0 0 0 35 (acetate) 35-40 (lactate)
Bicarb mmol/L 0 28 12 0 0
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which is shifted to lactic acid in case of low extracellular
pH. The uncharged form can enter the cell easily and
then dissociates in the neutral environment, forming
lactate and proton, resulting in profound and sustained
intracellular acidification (10). In addition, the lactate/
proton cotransporter of polymorphonuclear granulocytes
strongly increases the transport of lactate into the cells
in an acidic environment.
The second mechanism may be related to the presence
of an excess of lactate in comparison to its redox partner
pyruvate. In the PD fluid, the lactate level exceeds the
blood concentration 20 to 40 fold. Such high lactate:
pyruvate ratio can cause a reduction of the cell's entire
pyridine nucleotide system. In addition, the lactate
induces reduction of the cytosolic [NAD+]:[NADH] ratio
and its linked cytosolic phosphorylation potential of
[∑ATP]:[∑ADP][∑Pi] ratio. The phosphorylation
potential is the central energy source for the cell, and a
decrease in its value will impair many vital cellular
functions which include the distribution of inorganic ions
between intracellular and extracellular fluid (11,12). It
is generally believed that the cytotoxicity of lactate is
highly dependent upon the pH of the solution, indicating
that either passive or active diffusion across the cell
membrane determines the effects of lactate.
In order to solve the problem of cytotoxicity induced by
lactate and low pH, bicarbonate (the physiological buffer
of human body) is being used as the buffer. In the past,
its use was impeded by one major problem. At a pH of
greater than 7.0 during autoclaving, sodium bicarbonate
will react with calcium chloride to form insoluble salt
calcium carbonate. Two methods have been developed
recently to solve such problem. The first one is using a
double chamber bag system (13). The acid compartment
contains calcium chloride, magnesium chloride, acetic
acid and glucose; the base compartment contains sodium
chloride and sodium bicarbonate. There is a valve
between these two compartments which allows their
mixing immediately prior to instillation of the dialysate.
The second method is using dipeptide glycylglycine to
stabilize the bicarbonate dialysis solutions (14). After
solving such technical problem, in vivo and animal model
biocompatibility tests have been done and they showed
that bicarbonate-buffered solutions have better
biocompatibility (15-19).
Feriani et al performed a long-term randomized clinical
trial of using bicarbonate-buffered PD solution (20). No
adverse events were encountered with the use of the
bicarbonate-buffered solution. Subjective patient well-
being was improved due to reduction in abdominal pain.
Those acidotic patients using bicarbonate-buffered
solution showed increment in plasma bicarbonate level
while those patients using lactate-based solution did not
show any change. There was also a significant increase
in normalized protein catabolic rate in the bicarbonate
group. This may be due to the anabolic effect of acidosis
correction. In summary, this study suggests the efficacy
and safety of bicarbonate-buffered peritoneal solution.
There is additional study (21) showing that two-
chambered bicarbonate lactate-buffered PD fluids have
better biocompatibility due to reduced glucose
degradation products (GDP). The formation of GDP is
dependent on several factors like glucose concentration,
pH, type of buffer, duration of heat sterilization, storage,
catalyst, etc. In two-chamber model, high concentration
of glucose at pH around three is sterilized in a
compartment separated from the buffer compartment at
a higher pH. Upon mixing the two compartments, a fluid
with relatively higher pH and markedly reduced GDP
can be produced. Bicarbonate-buffered dialysis fluid is
also shown to improve the diffusion capacity of the
peritoneum with respect to lactate (22).
Summarizing the above studies, bicarbonate, replacing
lactate, seems to be the future trend of buffer used in
dialysis fluid. However, some investigators revealed that
the bicarbonate-based solutions are not optimal regarding
biocompatibility, presumably due to the paradoxical
intracellular acidification caused by influx of carbon
dioxide. So the effect of other buffers like pyruvate,
Carbicarb and histidine are being examined. Pyruvate is
especially a promising new buffer candidate.
Mahiout et al investigated the effect of pyruvate as a
buffer (23). They found that pyruvate-based dialysis fluid
minimizes the cytotoxicity effect on peripheral and
peritoneal leukocytes. The improved parameters included
O2-production, chemotactic response, cytokine-mRNA
detection and cytokine synthesis after stimulation.
Furthermore, in the presence of glucose, leukocyte
activation increases when pyruvate is present in the
dialysate, but not in the presence of lactate. Pyruvate
seems to be an alternative effective energy substrate
necessary for leukocyte activation, a process not
influenced by the Crabtree effect (see below).
Carbicarb is a formulated buffer that is a combination of
0.33 M sodium carbonate and 0.33 M sodium
bicarbonate. It has intracellular neutralizing effect in rat
model of systemic acidosis (24) and such effect has been
postulated to result from actual reduction of intracellular
CO2, a phenomenon that has been observed in in vitro
studies on whole blood in a closed system. This effect of
Carbicarb to lower pCO2 is a consequence of the
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carbonate reaction with protons (ie dissolved CO2) to
form bicarbonate. That the arterial pCO2 did not decrease
with Carbicarb may be related to dissociation of cellular
and arterial pCO2, a phenomenon that has been well
described in cardiac arrest. So, Carbicarb is a candidate
for future biocompatibility test.
Effects of Osmolality-osmotic Agents
Although dextrose is cheap and safe, its absorption leads
to short-lived ultrafiltration and metabolic complications
like obesity, hyperlipidemia and hyperinsulinemia. High
glucose level is also bio-incompatible. Glucose toxicity
can be due to the combined effects of hyperosmolality
and glycosylation of proteins to form advanced glycation
end-products (25). The biochemical mechanism of
glucose toxicity may be related to the Crabtree effect.
The Crabtree effect is a manifestation of respiratory
inhibition in the presence of high glucose concentration
or other hexose that is capable of being phosphorylated
by hexokinase (26). It includes the contraction of
mitochondria and a decrease in the rate of glucose
utilization occurring at the time of respiratory inhibition.
It may cause inadequate energy generation by decreasing
the availability of nicotinamide adenine dinucleotide and/
or oxidative potential, which may subsequently depress
lactate oxidation to pyruvate. The possible mechanisms
for Crabtree effect include competition between glycogen
and respiration for adenosine diphosphate or inorganic
phosphate, change of intracellular pH, change in
permeability of mitochondrial membrane, specific
regulatory behavior of glycolytic enzyme and specific
enzyme topography within the cell. Calcium may play a
role in the Crabtree effect. The mechanism is that glucose
increases cytoplasmic concentration of calcium and this
causes accumulation of calcium in the mitochondria. The
loading of mitochondria with calcium leads to increased
association of the inhibitory subunit with F1F0 which
result in inhibition of coupled respiration.
Due to the undesirable effects of glucose, other high
molecular weight osmotic agents have been tried. These
include amino acids, peptides, plasma substitutes,
albumin, synthetic polymers, glucose polymers.
Amino Acids
PD fluids containing amino acids have been shown to
be effective in improving the nitrogen balance and serum
proteins in malnourished patients (28), replacing the
peritoneal losses of proteins and amino acids, and
reduction of carbohydrate calories. There is no
ultrafiltration advantage over glucose.
Icodextrin (Glucose Polymers)
Glucose polymers are large molecular weight
oligosaccharide produced from hydrolyzed cornstarches.
When used in CAPD, icodextrin (7.5% solution; MW
20000, iso-smotic) causes sustained ultrafiltration for up
to 12 hours by colloid osmosis. It was superior to glucose
in terms of ultrafiltration over the 12-hour period (29).
No clinical side effect was observed. However, it is not
shown to have a better biocompatibility than glucose (9).
Icodextrin is usually used for those patients who have
lost ultrafiltration, diabetic patients and patients on
automated PD during the "dry" daytime dwell (30). When
it is used during peritonitis, there is no effective loss of
ultrafiltration since glucose polymer is acting at the small
pore rather than at the transcellular water channel (three-
pore theory). The three-pore theory means that besides
the small pores and the large pores for solute transport,
the peritoneal membrane has a third pathway, aquaporins
available for water transport but rejecting solute.
Others
Other osmotic substances include xylitol, sorbitol,
fructose and raffinose (31). They are all still under
investigation for their biocompatibility and side effects.
Ionic Composition
Sodium Concentration
The conventional sodium concentration is around 130
mmol/L to 140 mmol/L. If solutions of lower sodium
concentration are used, it may be possible to facilitate
the removal of sodium and increase ultrafiltration. In
addition, anti-hypertensive effect has been shown by
using low sodium concentration (120 mmol/L) on CAPD
patients (32).
Calcium
Patients using dialysis solutions of 1.75 mmol/L calcium
are in significant positive calcium balance even before
considering the additional calcium absorption of oral
calcium carbonate and vitamin D therapy. So the amount
of calcium carbonate needed to bind phosphate will lead
to hypercalcemia. Recently, the use of low calcium
dialysate (1.25 mmol/L) is a logical choice as its calcium
concentration is close to the serum ionized calcium level.
There are clinical studies showing that low calcium
dialysis solution can minimize hypercalcemia. However,
not all patients require the 1.25 mmol/L calcium solution.
One-third of patients can have good calcium phosphate
control even on 1.75 mmol/L calcium solution while
another third require even lower calcium solutions (0.6-
1.0 mmol/L) to avoid hypercalcemia while on vitamin
D therapy. The effect of low calcium dialysis solution
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on controlling bone disease is still controversial. Some
studies showed that parathyroid hormone will be elevated
while others show improvement. Actually the most
important factor controlling the parathyroid hormone is
the phosphate control. The use of low calcium dialysis
solution is not associated with any increase in risk of
peritonitis.
Additives to PD Solution
As PD is a process of continuous injury followed by
regeneration, additives to PD solution may be one way
to protect the peritoneum. Glycosaminoglycans are
shown to prevent peritoneal damage (33). It can also
decrease the protein loss in peritoneal fluid and increase
dialysis of creatinine (34). Another additive under study
is procysteine, a precursor of glutamine. It is an important
antioxidant that mops up the free radicals. So addition
of it to PD solutions can enhance biocompatibility of
PD solutions and protect mesothelial cell from the
oxidative damage during peritonitis (35). Antioxidants
may also help to prevent loss of ultrafiltration, fibrosis,
inflammation and protein loss that occur during or
immediately after peritonitis. Atrial natriuretic peptide
was shown to improve the ultrafiltration and sodium
clearance significantly in rat model (36). Thus additives
to PD solution is one possible way to achieve the ideal
PD fluid.
Gene Therapy
Henderson (37) pointed out that machine-based options
for automated PD will gradually give way to gene therapy
using the mesothelial cell (38,39) as a site for the
placement of nitrogen-fixing metabolic architecture that
is now resident in both prokaryotic and eukaryotic
microorganisms. Presumably, urea, uric acid, creatinine
and other organic sources for nitrogen as well as
inorganic toxins, such as sulfate, phosphate and hydrogen
ion will be consumed to synthesize amino acids,
polypeptides, and/or proteins. These anabolites can serve
as osmotic agents as well as a source of protein nutrition.
One may then envision a perpetual hamburger that on
initial ingestion would in its molecular components be
indefinitely recycled.
Other possible aspects of gene therapy include
implantation of the erythropoietin gene with its
regulatory sequence (40), implantation of metabolic
architecture of proximal tubule that capture and
metabolize beta-2-microglobulin, or adding other renal
metabolic functions such as vitamin D metabolism and
insulin catabolism.
CONCLUSION
The various studies cited here reveal that the current PD
solutions have poor biocompatibility and limitations due
to low pH, lactate as buffer, high osmolality, glucose
and advanced glycosylation end-products (Table 2). All
these factors have adverse effect on the peritoneal
immune system, making the patients more prone to
peritonitis. In addition, they also have damaging effect
on the peritoneum, making it not efficient for dialysis.
The risk of ultrafiltration failure increases from 2.6%
after 1 year to 30.9% after 6 years of CAPD treatment
(41).
More attention should be paid to looking for an ideal
biocompatible PD fluid that has no deleterious effect on
Table 2. Drawbacks of current PD solutions.
Lactate toxicity : Direct intracellular acidification and effect on
     cellular metabolism
Low pH : Lactate toxicity depends on a low pH
High glucose : Crabtree effect and advanced glycosylation
    end-products
High osmolality : In vitro cell damage and impairment of
    host defense
Ultrafiltration : Short duration of action
Table 3. Features of ideal PD fluid.
Features of ideal PD fluid Strategy
Treat malnutrition Amino acid
Help the clinical management of cardiovascular risk Low sodium dialysate
Provide adequacy of PD, More biocompatible solutions
Preserve peritoneal membrane structure,
No inhibitory effect on peritoneal immune system
Provide adequate ultrafiltration Icodextrin
Atrial natriuretic peptide
Protect peritoneum from continuous injury Glycosaminoglycans or procysteine added to PD solution
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peritoneal immune system and viability of peritoneal
membrane. It should also provide better ultrafiltration,
solute clearance, nutrition and dialysis adequacy (Table
3). The potential targets for improvement are the choice
of the buffer and osmotic agent, the ionic composition
of the fluids, additives to the fluids and gene therapy.
While searching for such ideal solution, we should bear
in mind the potential side effects after improving the
biocompatibility of the PD solutions. For example, the
bacterial growth may be promoted in such solutions and
hence increase the risk of peritonitis. Furthermore, the
inflammatory reactions may be enhanced due to
improved function of the immunocompetent cells in a
biocompatible environment. All future research for new
solutions should hence take into account of such potential
side effects of the improved biocompatibility.
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